Why Repligen Corporation (RGEN) stock moved
Repligen Corporation (RGEN) shares tumbled 7.7% to $174.11 as of October 30, 2026, a significant decline from the prior close of $188.64. BestStocks flagged the session as a major change for RGEN. Below, we break down what changed for RGEN, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
RGEN fell 7.7% to $174.11
Repligen announced a $1 billion private convertible senior notes offering (Globe Newswire), triggering an 8.56% intraday decline from $188.64 to $172.49. Volume surged to 1.55M shares—7.71x the typical level at this stage of the session—signaling heavy seller participation. Repligen earnings on November 3, 2026 (consensus EPS $0.46); management commentary on use of proceeds and any updated guidance.
What it means for Repligen Corporation investors
For Repligen Corporation investors, the recent signals add up to a strong bearish shift. On the constructive side: Positive price momentum. Weighing against that: Material negative event; Sharp 7.7% decline — elevated risk. Wall Street's consensus price target sits at $188.67, implying +8.4% upside from $174.11. BestStocks rates the overall signal quality medium (61/100). With earnings roughly 116 days out, the next report is the most likely near-term test of the move.
RGEN price reaction
RGEN last traded at $174.11, down $14.53 (-7.70%) from the previous close of $188.64. The session traded on 1.4× average volume (normal), so participation was unremarkable. Over the past month the stock has ranged between $163.84 and $194.57, and it currently sits about 33% of the way up that band.
Bullish and bearish analyst opinions on Repligen Corporation (RGEN)
The consensus analyst price target on Repligen Corporation (RGEN) is $188.67, 8.4% above the recent $174.11. Over the past 90 days analysts logged 0 upgrades, 4 maintains, and 0 downgrades. Here is how the bullish and bearish cases on RGEN line up.
The bullish case
- Wall Street's consensus price target of $188.67 implies +8.4% upside from $174.11.
- The Street's most bullish target is $225.00 (+29.2%).
- Positive price momentum.
The bearish case
- The most bearish analyst target is $142.00 (-18.4%).
- Material negative event.
- Sharp 7.7% decline — elevated risk.
- Repligen announced a $1 billion private convertible senior notes offering (Globe Newswire), triggering an 8.56% intraday decline from $188.64 to $172.49.
- Repligen completed its acquisition of BioLife Solutions, announced today via Globe Newswire and formalized in an SEC 8-K filing.
Weighing both sides, BestStocks' composite read of recent signals is strongly bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 30, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for RGEN
In-depth RGEN event analyses
Frequently asked questions about RGEN
Why did Repligen Corporation (RGEN) stock move?
RGEN tumbled 7.7% to $174.11. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.
How much did RGEN stock fall?
RGEN lost 7.70% ($14.53) versus the prior close of $188.64, last trading at $174.11 on 1.4× average volume.
When is Repligen Corporation's next earnings date?
RGEN's next earnings report is estimated for 2027-02-23 — about 116 days away.
What is the analyst price target for RGEN?
The consensus analyst price target for RGEN is $188.67, about 8.4% above the current $174.11. Over the past 90 days, analysts recorded 0 upgrades, 4 maintains, and 0 downgrades.
How BestStocks tracks RGEN
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared RGEN-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for RGEN, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 30, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.